| Symbol | KMDA |
|---|---|
| Name | KAMADA LTD |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Pharmaceutical Preparations |
| Address | 2 HOLTZMAN ST., SCIENCE PARK, REHOVOT, L3 7670402 |
| Telephone | 97289406472 |
| Fax | 08-9406473 |
| mosheb@kamada.com | |
| Website | https://www.kamada.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ;TASE |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001567529 |
| Description | Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics. Additional info from NASDAQ: |
Dividend of $0.17 Per Share,Record date: August 27, 2026, payable date: September 17, 2026
Read moreKamada Reports Record-High First Half and Second Quarter 2026 Financial Results
Read moreSecond Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
Read moreKamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
Read moreNOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON August 5, 2026,
Read moreKamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
Read moreKamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance Expecting Significantly Stronger Remainder of the Year
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03172455 | Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Stero… | — | Acute-graft-versus-host Disease | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06958796 | Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV) | Phase4 | Cytomegalovirus | Recruiting | 2025-11-27 | 2028-05-31 | ClinicalTrials.gov |
| NCT07009548 | CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients | Phase4 | Cytomegalovirus (CMV) Infection | Enrolling_By_Invitation | 2025-06-26 | 2027-12-01 | ClinicalTrials.gov |
| NCT04550325 | Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19 | Phase1 | Covid19 | Completed | 2020-08-05 | 2020-11-26 | ClinicalTrials.gov |
| NCT04204252 | Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation" | Phase3 | Alpha 1-Antitrypsin Deficiency | Terminated | 2019-11-25 | 2026-02-27 | ClinicalTrials.gov |
| NCT02956122 | A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD | Phase2 | Graft Versus Host Disease | Terminated | 2017-04-26 | 2018-05-03 | ClinicalTrials.gov |
| NCT02912845 | Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies… | Phase3 | Rabies | Completed | 2016-08-01 | 2019-11-13 | ClinicalTrials.gov |
| NCT02614872 | Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in … | Phase2 | Transplantation, Lung Rejection | Completed | 2016-07-26 | 2019-05-07 | ClinicalTrials.gov |
| NCT02005848 | Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabet… | Phase2 | New Onset Type-1 Diabetes | Completed | 2014-04-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02001688 | Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inh… | Phase2 | Alpha-1 Antitrypsin Deficiency | Completed | 2014-04-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02040090 | Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies V… | Phase2 | Rabies | Completed | 2013-04-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01661192 | Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in T… | Phase2 | Type 1 Diabetes | Completed | 2013-01-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01304537 | Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 D… | Phase1 | Type 1 Diabetes Mellitus | Completed | 2011-06-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01217671 | International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha… | Phase2 | Emphysema | Completed | 2009-12-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT00499837 | Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT )… | Phase2 | Cystic Fibrosis | Completed | 2007-09-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00460096 | Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individua… | Phase2 | Alpha 1-Antitrypsin Deficiency | Completed | 2007-03-01 | 2007-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Alpha 1-Antitrypsin Deficiency | TERMINATED | NCT04204252 |
| Alpha 1-Antitrypsin | Other | Phase PHASE3 | Alpha 1-Antitrypsin Deficiency | TERMINATED | NCT04204252 |
| Cytogam | Other | Phase PHASE4 | Cytomegalovirus (CMV) Infection | ENROLLING_BY_INVITATION | NCT07009548 |
| Alpha-1 Antitrypsin 80mg (AAT, Glassia®) | Other | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01304537 |
| Alpha-1 Antitrypsin 60mg (AAT, Glassia®) | Other | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01304537 |
| Alpha-1 Antitrypsin 40mg (AAT, Glassia®) | Other | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01304537 |
| AAT( Alpha 1 Antitrypsin) | Other | Phase PHASE2 | Type 1 Diabetes | COMPLETED | NCT01661192 |
| Placebo | Other | Phase PHASE2 | New Onset Type-1 Diabetes | COMPLETED | NCT02005848 |
| Alpha-1 Antitrypsin | Other | Phase PHASE2 | New Onset Type-1 Diabetes | COMPLETED | NCT02005848 |
| Placebo | Other | Phase PHASE2 | Emphysema | COMPLETED | NCT01217671 |
| Kamada AAT for inhalation | Other | Phase PHASE2 | Emphysema | COMPLETED | NCT01217671 |
| Kamada-AAT for Inhalation, 160mg | Other | Phase PHASE2 | Alpha-1 Antitrypsin Deficiency | COMPLETED | NCT02001688 |
| Placebo | Other | Phase PHASE2 | Alpha-1 Antitrypsin Deficiency | COMPLETED | NCT02001688 |
| Kamada-AAT for Inhalation, 80mg | Other | Phase PHASE2 | Alpha-1 Antitrypsin Deficiency | COMPLETED | NCT02001688 |
| Glassia | Other | Preclinical | Acute-graft-versus-host Disease | NO_LONGER_AVAILABLE | NCT03172455 |
| Kamada Anti-SARS-CoV-2 | Other | Phase PHASE1 | Covid19 | COMPLETED | NCT04550325 |
| Albumin | Other | Phase PHASE2 | Graft Versus Host Disease | TERMINATED | NCT02956122 |
| methylprednisolone or equivalent steroid | Other | Phase PHASE2 | Graft Versus Host Disease | TERMINATED | NCT02956122 |
| GLASSIA | Other | Phase PHASE2 | Graft Versus Host Disease | TERMINATED | NCT02956122 |
| GLASSIA® and Institution standard of care (SOC) | Other | Phase PHASE2 | Transplantation, Lung Rejection | COMPLETED | NCT02614872 |
| KamRAB - HRIG | Other | Phase PHASE3 | Rabies | COMPLETED | NCT02912845 |
| Active rabies vaccine (US-FDA approved) | Other | Phase PHASE2 | Rabies | COMPLETED | NCT02040090 |
| Cytogam | Other | Phase PHASE4 | Cytomegalovirus (CMV) Infection | ENROLLING_BY_INVITATION | NCT07009548 |
| Placebo | Other | Phase PHASE3 | Alpha 1-Antitrypsin Deficiency | RECRUITING | NCT04204252 |
| Alpha 1-Antitrypsin | Other | Phase PHASE3 | Alpha 1-Antitrypsin Deficiency | RECRUITING | NCT04204252 |
| Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months | Other | Phase PHASE4 | Cytomegalovirus | RECRUITING | NCT06958796 |
| Cytogam | DRUG | Phase PHASE4 | Cytomegalovirus (CMV) Infection | ENROLLING_BY_INVITATION | NCT07009548 |
| Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months | DRUG | Phase PHASE4 | Cytomegalovirus | RECRUITING | NCT06958796 |
| Kamada Anti-SARS-CoV-2 | BIOLOGICAL | Phase PHASE1 | Covid19 | COMPLETED | NCT04550325 |
| Alpha 1-Antitrypsin | DRUG | Phase PHASE3 | Alpha 1-Antitrypsin Deficiency | RECRUITING | NCT04204252 |
| Glassia | DRUG | Preclinical | Acute-graft-versus-host Disease | NO_LONGER_AVAILABLE | NCT03172455 |
| Albumin | BIOLOGICAL | Phase PHASE2 | Graft Versus Host Disease | TERMINATED | NCT02956122 |
| methylprednisolone or equivalent steroid | DRUG | Phase PHASE2 | Graft Versus Host Disease | TERMINATED | NCT02956122 |
| GLASSIA | BIOLOGICAL | Phase PHASE2 | Graft Versus Host Disease | TERMINATED | NCT02956122 |
| KamRAB - HRIG | DRUG | Phase PHASE3 | Rabies | COMPLETED | NCT02912845 |
| GLASSIA® and Institution standard of care (SOC) | DRUG | Phase PHASE2 | Transplantation, Lung Rejection | COMPLETED | NCT02614872 |
| Active rabies vaccine (US-FDA approved) | DRUG | Phase PHASE2 | Rabies | COMPLETED | NCT02040090 |
| Alpha-1 Antitrypsin | BIOLOGICAL | Phase PHASE2 | New Onset Type-1 Diabetes | COMPLETED | NCT02005848 |
| Kamada-AAT for Inhalation, 160mg | DRUG | Phase PHASE2 | Alpha-1 Antitrypsin Deficiency | COMPLETED | NCT02001688 |
| Kamada-AAT for Inhalation, 80mg | DRUG | Phase PHASE2 | Alpha-1 Antitrypsin Deficiency | COMPLETED | NCT02001688 |
| AAT( Alpha 1 Antitrypsin) | DRUG | Phase PHASE2 | Type 1 Diabetes | COMPLETED | NCT01661192 |
| Alpha-1 Antitrypsin 80mg (AAT, Glassia®) | DRUG | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01304537 |
| Alpha-1 Antitrypsin 60mg (AAT, Glassia®) | DRUG | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01304537 |
| Alpha-1 Antitrypsin 40mg (AAT, Glassia®) | DRUG | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01304537 |
| Placebo | DRUG | Phase PHASE3 | Alpha 1-Antitrypsin Deficiency | RECRUITING | NCT04204252 |
| Kamada AAT for inhalation | BIOLOGICAL | Phase PHASE2 | Emphysema | COMPLETED | NCT01217671 |
| Aerosolized, human, plasma-derived Alpha-1 Antitrypsin | DRUG | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT00499837 |
| Kamada-API | DRUG | Phase PHASE2 | Alpha 1-Antitrypsin Deficiency | COMPLETED | NCT00460096 |